Acitretin

Active ingredient description

Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
D05BB02
Acitretin
D Dermatologicals → D05 Antipsoriatics → D05B Antipsoriatics for systemic use → D05BB Retinoids for treatment of psoriasis
Discover more medicines within D05BB02

Medicines

Acitretin is the active ingredient of these drugs:

Drug
Countries
ACITREN

Poland

KERACUTAN

Austria

NEOTIGASON

Australia Brazil Finland Hong Kong Ireland

NOVATIN

Australia

NOVATRETIN

New Zealand Singapore

SORIATANE

Canada France United States

SORIF

Hong Kong

ZETIN

Australia

ZORIAS

Italy

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
SORIATANE Capsule
Structured Product Labeling (SPL)
US
ACITRETIN Capsule, hard
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

LCH760E9T7 - ACITRETIN

CAS registry number

55079-83-9 - acitretin

SNOMED-CT

386938006 - Acitretin (substance)

Next: Usage